Ian Jones

SPCs: Waive goodbye to your protection

In Europe, Supplementary Protection Certificates (SPCs) compensate patentees for the inevitable delay in obtaining Marketing Authorisation by extending exclusivity for a marketable pharmaceutical or plant protection product by up to five years (five-and-a-half years for paediatric medicines) following the expiry of the related patent protection. Earlier this year, the EU...

Read more

Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals has announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and...

Read more

CJEU: No SPCs for new formulations of marketed active ingredients

The CJEU has provided further, somewhat limited, guidance on what pharmaceutical products may be awarded a Supplementary Protection Certificate (SPC), and the associated market exclusivity, in Europe. According to the CJEU, an earlier marketing authorisation issued for an active ingredient prevents an SPC being granted for a new formulation of...

Read more

Patent licensing trends in the UK pharmaceutical sector

2018 was billed by some in the industry as the year of pharma M&As. However, as of September, we still haven’t seen the acquisition values that were expected following a rather barren 2017. What we have seen are record high patent licensing deals. If your company is built on a...

Read more

Little-known trouble at European Patent Office should put start-ups and investors alike on alert

The European Patent Office (EPO), the body responsible for ruling on patent applications submitted by companies across the continent, has come under fire recently as a result of growing concerns about the quality of patents it has been granting. While the EPO’s management team has celebrated recent increases in the overall number of patents granted as...

Read more